Boehringer Accused Of Withholding Royalties As Trial Starts
Pharmaceutical licensing company Royalty Pharma kicked off a patent trial Monday by saying German drugmaker Boehringer Ingelheim has unlawfully withheld royalties for its diabetes treatment under the false assertion that fees...To view the full article, register now.
Already a subscriber? Click here to view full article